NeuBase Therapeutics, Inc. reported financial results for the fiscal year ended September 30, 2019. For the fiscal year ended September 30, 2019, the Company reported a net loss of approximately $27.0 million, or $3.26 per share, compared to a net loss of approximately $0.04 million, or $0.01 per share, for the period from inception (August 28, 2018) to September 30, 2018.